Lumbar Degenerative Disc Disease Treated With Anterior Tension Band System (ATB) With ALIF/FRA Spacer

This study has been completed.
Sponsor:
Information provided by:
Synthes USA HQ, Inc.
ClinicalTrials.gov Identifier:
NCT01323387
First received: March 23, 2011
Last updated: July 1, 2011
Last verified: July 2011

March 23, 2011
July 1, 2011
April 2004
May 2009   (final data collection date for primary outcome measure)
Radiographic fusion [ Time Frame: Up to 24 Months ] [ Designated as safety issue: No ]
CT Scans and plain film x-rays will be evaluated. Demonstration of bridging trabecular bone through or external to the allograft spacer will be the measure of success.
Radiographic fusion [ Time Frame: 24 Months Post-op ] [ Designated as safety issue: No ]
CT Scans and plain film x-rays will be evaluated. Demonstration of bridging trabecular bone through or external to the allograft spacer will be the measure of success.
Complete list of historical versions of study NCT01323387 on ClinicalTrials.gov Archive Site
  • Quality of Life using the SF-12 Scale [ Time Frame: up to 24 months ] [ Designated as safety issue: No ]
  • Pain Scores on the Visual Analog Scale [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
  • Functional improvement using the Oswestry Disability Index [ Time Frame: up to 24 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Lumbar Degenerative Disc Disease Treated With Anterior Tension Band System (ATB) With ALIF/FRA Spacer
Lumbar Degenerative Disc Disease Treated With

Multi-center, prospective nonrandomized study of treatment for 1 and 2 level degenerative disc disease between L2 and S1. Patients will be followed for a minimum of 2 years.

The primary objective of this study to measure fusion success in patients with lumbar degenerative disc disease using the ATB and ALIF/FRA Spacer. The Secondary objective is evaluation of the patient's quality of life, pain and function.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Lumbar Degenerative Disc Disease
Device: Interbody Fusion
allograft spacer + anterior plate
Other Names:
  • ATB
  • Anterior Tension Band
Treatment
Interbody fusions with Anterior Plating
Intervention: Device: Interbody Fusion
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
February 2011
May 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. One or Two level (consecutive) degenerative disc disease between L2 and S1. Degenerative disc disease is defined as follows:

    Chronic pain (confirmed by patient exams and history) of discogenic origin, confirmed by radiographic evidence (e.g. MRI, discogram) two or more of the following:

    • Modic type 2 endplate changes on T2 weighted MRI
    • high intensity zone signal on T2 weighted MRI
    • positive discogram with negative controls
    • dark disc (diminished T2 weighted signal)
    • decreased disc height
  2. Has experienced pain, functional deficit and/or neurological deficit for a minimum six month period of time prior to enrollment
  3. Has failed to respond to non-operative treatment modalities for a minimum three month period of time prior to enrollment
  4. Skeletally mature and at least 18 years of age
  5. Signs the approved Informed Consent Document
  6. Is available for long term follow-up and interval visits

Exclusion Criteria:

  1. Has more than 2 levels to be instrumented
  2. Has had a previous fusion attempt at the involved level(s)
  3. Has had more than two previous open, lumbar spine surgical procedures at the involved level(s)
  4. Currently implanted with anterior instrumentation at the involved level(s)
  5. Patient would be classified as morbidly obese BMI > 35
  6. Active localized or systemic infection
  7. Presence of a disease entity or condition which significantly affects the possibility of bony fusion (e.g., osteoporosis, metastatic cancer, long-term use of steroids, etc.)
  8. Has an immunosuppressive disorder
  9. Pregnant or interested in becoming pregnant during the study.
  10. Has a known sensitivity to device materials
  11. Mentally incompetent or prisoner
  12. Currently a participant in another study for the same indications.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01323387
1255
No
Damon Lees, Clinical Regulatory Manager, Spine Global Regulatory & Clinical Affairs, Synthes USA HQ. Inc.
Synthes USA HQ, Inc.
Not Provided
Principal Investigator: Kirkham Wood, MD Mass. General Hospital
Synthes USA HQ, Inc.
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP